For someone with a focus on biotechs, you haven't done enough DD here.
You need to come back with something more than opinion to have it considered. Your opinion is that I'm not keeping it real? On what basis?
You do realize that anticancer nanomicelles are entering Human clinical trials? Same technology, and we've discussed it here at length over the past 4 years. Those pioneering anticancer therapies are paving the way for antiviral nanomicelle therapy.
yes, Dengue will probably not meet FDA approval until 2014 to 2015. But, that doesn't mean it won't produce revenue for the company long before then. This isn't hype, it's SOP for small biotechs with cutting edge, paradigm changing IP.
News 
Market Data 
Discover 
